We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Abingdon Health Plc | ABDX | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 7.75 | 08:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 7.75 | 7.75 | 7.75 | 7.75 | 7.75 |
| Industry Sector |
|---|
| HEALTH CARE EQUIPMENT & SERVICES |
| Top Posts |
|---|
Posted at 17/5/2024 11:59 by z1co York, U.K. 15th May 2024: Abingdon Health plc (AIM: ABDX), a leading international lateral flow Contract Development and Manufacturing Organisation (CDMO), announces the launch of Boots own-brand, saliva pregnancy self-test across the UK and online, in partnership with Salignostics and Crest Medical.On 20th March 2024, Abingdon Health announced the launch of the first two Boots branded self-tests - Iron and Vitamin D deficiency - in-store and online at boots.com. In another step toward strengthening this partnership with Boots, Abingdon Health is now pleased to announce the launch of the first ever saliva pregnancy test under the Boots own brand range. The test is being made available in store and online at boots.com from Spring 2024 onwards. This product launch allows more people to access a new way of testing for pregnancy. With the UK pregnancy self-test market expected to reach USD $56.7 million by 20331, this provides a strategic opportunity to launch, on an own-brand basis, an innovative product in this growing market with the UK's leading health and beauty retailer. With general consumer adoption of self-tests on the rise (US $7.89 billion in 2023)2, and a robust pipeline of products within its CRO/CDMO offering, Abingdon Health is well positioned to continue developing OEM retail relationships within the UK and Europe as a value-add, innovative Private Label Supplier (PLS). |
Posted at 15/3/2024 15:26 by daz TimboI thought the outlook statement was very misleading. Last year ABDX had a strong H2 weighting and it looks to be the same this year, so to say H2 will be materially ahead of H1 is meaningless. A comparison with H2 last year would have given investors a much better insight. Growth will not be 116% in H2 but I want to know 1. Will it be positive and 2. If positive, by roughly how much 20/30/40% etc. Also, the cash outflow in H1 was £1.238m and they only have £2m cash left. While the burn rate will be lower in H2, without better guidance, it becomes impossible for private investors to make an informed view on the H2 outflow. No doubt Brokers will have been greater insight but it's not much help to me. Based on the lack of clarity, I can't dismiss the need for another fund raise. |
Posted at 14/10/2023 13:42 by timbo003 Register for the seminar mentioned in the previous post (which includes a presentation from ABDX) here: |
Posted at 14/10/2023 10:45 by sharesoc ShareSoc is holding its first hybrid event in London on 19th Oct. Hear from Abingdon Health (ABDX) and other healthcare companies like Tristel Plc (TSTL), Inspiration Healthcare Group (IHC), Creo Medical Group (CREO) and GENincode (GENI). Attend in-person or online.📍 |
Posted at 11/4/2023 09:13 by mrmark1 In production now and launching in May with a big advertising campaign. Amazon and other sites/stores with co-branded products. ABDX is the exclusive sole manufacturer and distributor for the worlds first saliva pregnancy test for the UK. |
Posted at 07/10/2022 13:02 by bandflex The settlement agreement is in full and final settlement of the outstanding debt of GBP8.9m (excluding interest) and comprises:i) A contractually required cash payment of GBP6.3m from DHSC to Abingdon, which is required to be paid to the Company on or before 22 July 2022; GBP1.5m of this cash payment will be held under charge until the outcome of the judicial review is known; and... They received the £6.3m on 7/7/22, only £1.5m outstanding. That is their only interest in the case. |
Posted at 01/8/2022 12:53 by blackhorse23 Don't see any further in here so switched to high growth stocks MCL ( LSE) .... 5p to 20p many times last 6 month ... dividend yield & profitability is good .. |
Posted at 06/4/2022 12:24 by bobdown2 A very large sell followed by 2 small buys and the share price is in the top half of the spread. I suggest you look at todays trades to see how a sellers position unwinds.I need 12 pence to be in profit.i have made four trades in three or four days. And today the markets found out that abdx is still working with avacta. A payment from the DHSC could double the share price at these levels. But I think they are drawing the process out to lower the settlement. Still contracts look to be arriving and abdx look to have come through the mess. |
Posted at 05/4/2022 07:20 by tomboyb Abingdon Health plc("Abingdon" or "the Company") Completion of Technical Transfer to full-scale manufacture and initial orders for Vatic KnowNowTM test Tests manufactured by Abingdon now authorised for sale York, U.K. 5 April 2022: Abingdon Health plc (AIM: ABDX), a leading international developer and manufacturer of high quality and effective rapid tests, announces it has successfully completed the technical transfer of the Vatic KnowNowᵀ test (Spike Test in USA) on behalf of its customer, leading diagnostics technology innovator Vatic Health Limited ("Vatic"), on schedule. This follows the conclusion of the scale-up and manufacture of three independent production-scale batches and Vatic has now approved the sale of tests manufactured by Abingdon. Abingdon has received initial purchase orders from Vatic for commercial sale, and manufacturing for these orders will now commence. The Vatic KnowNowᵀ test is an easy-to-use saliva COVID-19 antigen test, which is the only test that identifies the virus by mimicking the surface of a human cell. This means the test only identifies "live" or "active" copies of the virus which are capable of cell entry and thereby infecting a human cell. Other tests, such as PCR and lateral flow antigen tests, can pick up harmless viral fragments with the potential for users to test positive once they are no longer infectious. Furthermore, the unique detection mechanism of the KnowNowᵀ test has been purposefully designed to be more robust to mutation than traditional antigen tests, making it more future-proofed for ongoing COVID-19 testing. Vatic have previously announced that this test detects variants of the SARS-CoV-2 virus including the Omicron variant. The test is CE marked for professional use and has been submitted by Vatic to the US FDA for Emergency Use Approval (EUA). Alex Sheppard, CEO of Vatic Health Limited, commented: "We are excited to have concluded the transfer of our product to manufacture with Abingdon and to commence sales of our product. Our proprietary technology allows ease of use via a saliva specimen and only detects active virus -enabling individuals to know their infectivity status." Dr Mona K. Omir, CTO of Vatic Health Limited, commented: "Completing the Technical Transfer of the KnowNow test is a huge milestone in the Vatic Health journey and our ongoing collaboration with Abingdon Health. To bring such novel assay technology into routine manufacturing could be a true step change in diagnostics and we are excited for what this could mean for COVID-19 testing around the world." Chris Yates, CEO of Abingdon Health plc, commented: "We are delighted to have concluded this technical transfer and to begin manufacture of the product for Vatic at our Yorkshire facilities. This is an important addition to the COVID-19 testing toolbox and we look forward to continuing to work with Vatic as we manufacture the product to fulfil their requirements." |
Posted at 02/4/2022 09:26 by 74tom Always starts to pique my interest when a shorter appears to have a ‘god’ complex…We saw a major short squeeze here last August from 27-85p and saw a number of smaller pops up to the long term downtrend line along the way. The mid March bounce to 16p took ABDX clear of the downtrend resistance that had been in place since Dec 2020, which like it or not is a bullish sign. Some other points; - No, they didn’t wait as long as possible to release their final results, they have until 30th June (6 months post year end) - many examples of companies yet to report - SNG, AVCT being two off the top of my head. - Yesterdays £50m ONT settlement shows DHSC were waiting until the new budget year to settle the disputes, so there is now a real prospect of getting the £8.4m + 8% interest on the overdue amounts… - You seem to think this is priced in, I’d argue that 99% of day traders will have forgotten this exists and last remember it being in the 30/40/50p range so will pile in on the news, similar to recent 100/200% moves we’ve seen in AVCT & GDR, and cause a major spike. Also a stock that has had a short squeeze once is far more likely to have a second, especially from a lower level (traders that did well then will look to repeat the trick…) The place to short would then be the top of said spike… being short now is just asking for a margin call. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
